ReviewReviews in endocrine & metabolic disorders2022
Obesity, type 2 diabetes, and testosterone in ageing men.
Review in Reviews in endocrine & metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review.International journal of molecular sciences · 2024Pooled it
- Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism.The Journal of clinical endocrinology and metabolism · 2025Trial
- Association between a novel nutritional-inflammatory index and testosterone levels: a cross-sectional study.Sexual medicine · 2026Article
- Increasing skeletal muscle mass and strength during incretin-based weight loss.Obesity pillars · 2026Article
- The link between diabetes and male infertility: mechanisms and implications.Scientific reports · 2026Article
- Late-onset and functional hypogonadism in aging men: an integrated perspective on hormonal, sleep, and metabolic dimensions.Journal of endocrinological investigation · 2026Review
- System-level clustering of testosterone-related biomarkers identifies high-risk aging profiles linked to inflammation and renal function.Communications medicine · 2026Article
- Sex-Specific Oral Health: A Narrative Review of Hormonal Influences and Disease Patterns.Dentistry journal · 2026Review
- Review
- The mediating role of testosterone in the relationship between body fat percentage and diabetes mellitus risk.Frontiers in endocrinology · 2026Article
- Review
- The effects of testicular aging on Leydig cells and the application of stem cells in restoring Leydig cells function.Reproductive biology and endocrinology : RB&E · 2025Review
- Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes.Journal of clinical medicine research · 2025Review
- Association between circulatory immune cell to high-density lipoprotein cholesterol ratios and testosterone level in adult men: findings from NHANES 2011-2016.BMC endocrine disorders · 2025Article
- Awareness and prevalence of the symptoms of testosterone deficiency: a cross-sectional survey of community-dwelling men in the UK.BMJ open · 2025Article
- Global, regional and national level burden of bulimia nervosa from 1990 to 2021 and their projections to 2030: analysis of the global burden of disease study.Journal of eating disorders · 2025Article
- From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections.Reviews in endocrine & metabolic disorders · 2025Review
- Article
- Investigating the role of the metabolic score for visceral Fat in assessing the prevalence of chronic kidney disease from the NHANES 1999-2018.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the absence of obesity, adverse lifestyle behaviours, and use of medication such as opioids serum testosterone concentrations decrease by only a minimal amount at least until very advanced age in most men. Obesity is heterogeneous in its phenotype, and it is the accumulation of excess adipose tissue viscerally associated with insulin resistance, dyslipidaemia, inflammation, hypothalamic leptin resistance and gliosis that underpins the functional hypogonadism of obesity. Both central (hypothalamic) and peripheral mechanisms are involved resulting in a low serum total testosterone concentration, while LH and FSH are typically in the normal range. Peripherally a decrease in serum sex hormone binding globulin (SHBG) concentration only partially explains the decrease in testosterone and there is increasing evidence for direct effects in the testis. Men with obesity associated functional hypogonadism and serum testosterone concentrations below 16 nmol/L are at increased risk of incident type 2 diabetes (T2D); high testosterone concentrations are protective. The magnitude of weight loss is linearly associated with an increase in serum testosterone concentration and with the likelihood of preventing T2D or reverting newly diagnosed disease; treatment with testosterone for 2 years increases the probability of a positive outcome from a lifestyle intervention alone by approximately 40%. Whether the additional favourable benefits of testosterone treatment on muscle mass and strength and bone density and quality in the long-term remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.